Table 2 Allele frequency distribution of the COMT V158M polymorphism in the Australian and Polish HNPCC MMR mutation positive patients combined
Group | Val/Val (%) | Val/Met (%) | Met/Met (%) | n | Pearson's Chi-squared |
|---|---|---|---|---|---|
subject group | 86 (26.0) | 167 (50.5) | 78 (23.6) | 331 | Â |
hMLH1 mutation carriers | 48 (26.4) | 91 (50.0) | 43 (23.6) | 182 | p = 0.98 |
hMSH2 mutation carriers | 38 (25.5) | 76 (51.0) | 35 (23.5) | 149 | Â |
mutation type: truncation/deletion | 76 (26.7) | 144 (50.5) | 65 (22.8) | 285 | p = 0.65 |
mutation type: missense | 10 (21.7) | 23 (50.0) | 13 (28.3) | 46 | Â |
affected with CRC | 38 (25.5) | 79 (53.0) | 32 (21.5) | 149 | p = 0.50 |
unaffected with CRC | 47 (26.4) | 84 (47.2) | 47 (26.4) | 178 | Â |
unaffected with CRC (>45 years) | 15 (23.1) | 35 (53.8) | 15 (23.1) | 65 | p = 0.92** |
endometrial/ovarian cancer | 11 (29.7) | 18 (48.6) | 8 (21.6) | 37 | p = 0.66 |
affected with CRC and unaffected with endometrial/ovarian cancer* | 50 (23.0) | 112 (51.6) | 55 (25.3) | 217 | Â |